JP7902198B2 - 特定のｈｄａｃ６阻害剤及び、少なくとも一つのｃｔｌａ４チェクポイント阻害剤を含む組合せ - Google Patents

特定のｈｄａｃ６阻害剤及び、少なくとも一つのｃｔｌａ４チェクポイント阻害剤を含む組合せ

Info

Publication number
JP7902198B2
JP7902198B2 JP2023564130A JP2023564130A JP7902198B2 JP 7902198 B2 JP7902198 B2 JP 7902198B2 JP 2023564130 A JP2023564130 A JP 2023564130A JP 2023564130 A JP2023564130 A JP 2023564130A JP 7902198 B2 JP7902198 B2 JP 7902198B2
Authority
JP
Japan
Prior art keywords
ctla4
combination
itf3756
administered
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023564130A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024515100A5 (enExample
JP2024515100A (ja
Inventor
フォサーティ ジャンルカ
レオーニ フラヴィオ
サムエレ ポッツィ ピエトロ
ガルビアーティ エリザベッタ
ステインクーラー クリスティアン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Italfarmaco SpA
Original Assignee
Italfarmaco SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Italfarmaco SpA filed Critical Italfarmaco SpA
Publication of JP2024515100A publication Critical patent/JP2024515100A/ja
Publication of JP2024515100A5 publication Critical patent/JP2024515100A5/ja
Application granted granted Critical
Publication of JP7902198B2 publication Critical patent/JP7902198B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2023564130A 2021-04-20 2022-04-19 特定のｈｄａｃ６阻害剤及び、少なくとも一つのｃｔｌａ４チェクポイント阻害剤を含む組合せ Active JP7902198B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IT102021000009926 2021-04-20
IT102021000009926A IT202100009926A1 (it) 2021-04-20 2021-04-20 Una combinazione comprendente un inibitore di hdac6 specifico e almeno un inibitore del checkpoint ctla4
PCT/EP2022/060287 WO2022223543A1 (en) 2021-04-20 2022-04-19 A combination comprising a specific hdac6 inhibitor and at least one ctla4 checkpoint inhibitor

Publications (3)

Publication Number Publication Date
JP2024515100A JP2024515100A (ja) 2024-04-04
JP2024515100A5 JP2024515100A5 (enExample) 2025-03-14
JP7902198B2 true JP7902198B2 (ja) 2026-08-07

Family

ID=76808052

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023564130A Active JP7902198B2 (ja) 2021-04-20 2022-04-19 特定のｈｄａｃ６阻害剤及び、少なくとも一つのｃｔｌａ４チェクポイント阻害剤を含む組合せ

Country Status (17)

Country Link
US (1) US20240207228A1 (enExample)
EP (1) EP4326259A1 (enExample)
JP (1) JP7902198B2 (enExample)
KR (1) KR20230172001A (enExample)
CN (1) CN117177745A (enExample)
AR (1) AR125356A1 (enExample)
AU (1) AU2022262199A1 (enExample)
BR (1) BR112023021125A2 (enExample)
CA (1) CA3213275A1 (enExample)
CL (1) CL2023002894A1 (enExample)
CO (1) CO2023013780A2 (enExample)
IL (1) IL307649A (enExample)
IT (1) IT202100009926A1 (enExample)
MX (1) MX2023012030A (enExample)
PE (1) PE20242078A1 (enExample)
TW (1) TW202308609A (enExample)
WO (1) WO2022223543A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119424649A (zh) * 2024-02-29 2025-02-14 中山大学附属第一医院 假体周围感染治疗靶点及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019501205A (ja) 2016-01-11 2019-01-17 ターンストーン リミテッド パートナーシップ 腫瘍崩壊性ウイルス及びチェックポイント阻害剤の併用療法
JP2020516671A (ja) 2017-04-14 2020-06-11 イタルファルマコ ソシエタ ペル アチオニＩｔａｌｆａｒｍａｃｏ Ｓｏｃｉｅｔａ Ｐｅｒ Ａｚｉｏｎｉ 選択的ｈｄａｃ６阻害剤

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019501205A (ja) 2016-01-11 2019-01-17 ターンストーン リミテッド パートナーシップ 腫瘍崩壊性ウイルス及びチェックポイント阻害剤の併用療法
JP2020516671A (ja) 2017-04-14 2020-06-11 イタルファルマコ ソシエタ ペル アチオニＩｔａｌｆａｒｍａｃｏ Ｓｏｃｉｅｔａ Ｐｅｒ Ａｚｉｏｎｉ 選択的ｈｄａｃ６阻害剤

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
"P630 Induction of antitumor immuneresponse by selective HDAC6 inhibition"，34th Annual Meeting &Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2019):part 2 JOURNAL FOR IMMUNOTHERAPY OF CANCER，2019年，Vol.7(S1)，p.66-67，DOI: 10.1186/s40425-019-0764-0
Current opinion in investigational drugs，2005年，Vol.6, No.6，p.582-591

Also Published As

Publication number Publication date
CN117177745A (zh) 2023-12-05
CL2023002894A1 (es) 2024-03-15
TW202308609A (zh) 2023-03-01
CO2023013780A2 (es) 2023-11-10
WO2022223543A1 (en) 2022-10-27
IL307649A (en) 2023-12-01
US20240207228A1 (en) 2024-06-27
IT202100009926A1 (it) 2022-10-20
MX2023012030A (es) 2023-10-24
BR112023021125A2 (pt) 2023-12-12
JP2024515100A (ja) 2024-04-04
PE20242078A1 (es) 2024-10-18
EP4326259A1 (en) 2024-02-28
AR125356A1 (es) 2023-07-12
CA3213275A1 (en) 2022-10-27
KR20230172001A (ko) 2023-12-21
AU2022262199A1 (en) 2023-09-21

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231102

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250305

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250305

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260303

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260602

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260630

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260728

R150 Certificate of patent or registration of utility model

Ref document number: 7902198

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150